The issue of corporate social responsibility (CSR) of firms in their host community remains an unsettled academic debate. In developing states where multinational corporations (MNCs) are dominant actors, the issue is even more contested. Most importantly, MNCs’ profit motive, their support in their home country and the inability to hold them accountable to their host community/state’s aspirations present a direct clash with their innocent appearance and pretence of CSR. But why do MNCs need to be overloaded with the host community’s problems in the form of CSR when they are paying royalties, taxes, rents and other levies to their host states? Despite the fact that recent research in this field has shown how this correlates with the profit motive of these firms, contestation by state-corporations over public goods is not decided in favour of the bottom billion. This article observes attempts by the South African government to provide HIV/AIDS drugs at an affordable price based on recommendations by the World Trade Organization-Trade-Related Aspects of Intellectual Property Rights (WTO-TRIPS) between 1997 and 2014. By January 2014, MPCs, in their bids to effectively control the production of ARV as against generic licensing accommodated in the TRIPS agreement, started a campaign of calumny against South African government. This was aimed indirectly to influence the Proposed Draft National IP Policy of September 2013 that will make ARV cheaper in the country. The campaign was described by the South African Department of Health as a genocide attempt against South Africans.
AaronK. K. (2010). ‘Two theses on corporate social responsibility failure in the Niger Delta, Nigeria’, in AaronK. K.GeorgeD. (Eds), Placebo as medicine: The poverty of development intervention and conflict resolution strategies in the Niger Delta Region of Nigeria (pp. 158–177). Port Harcourt: Kemuele Publications.
2.
AcemogluD.RobinsonJ. A. (2012). Why nations fail: The origins of power, prosperity and poverty. London: Profile Books.
3.
AkinsanyaA. A. (1992). ‘Multinationals in a changing environment’, in LevineH. M. (Ed.), World politics debates: A reader in contemporary issues (pp. 46–51). New York: McGraw-Hill.
4.
BarrellH. (2000). Mbeki fingers CIA in AIDS conspiracy. Mail & Guardian, (Johannesburg, South Africa), October6.
5.
BartonJ. H.MaskusK. E. (2006). ‘Economic perspectives on a multilateral agreement on open access to basic science and technology’, in. EvenettS. J.HoekmanB. M. (Eds), Economic development & multilateral trade cooperation (pp. 349–368). Washington, DC: World Bank.
6.
BhagwatiJ. (2004). In defense of globalization. Oxford and New York: Oxford University Press.
7.
BondP. (2006). Looting Africa: The economics of exploitation. Pietermaritzburg: University of KwaZulu-Natal Press.
8.
BondP. (2005). Elite transition: From apartheid to neoliberalism in South Africa. Pietermaritzburg: University of KwaZulu-Natal Press.
9.
BondP. (2003). Against global apartheid: South Africa meets the World Bank, IMF and International Finance. Cape Town: University of Cape Town Press.
10.
ChikaneF. (2013). The things that could not be said: From A{ids} to Z{imbabwe}. Johannesburg: Picador Africa.
11.
ChikaneF. (2012). Eight days in September: The removal of Thabo Mbeki. Johannesburg: Picador Africa.
12.
Christian Aid. (2004). Behind the mask: The real face of corporate social responsibility. Retrieved 25February2013, from http://christianaid.org.uk//0401csr/csr_behindthemask.pdf
13.
DeeganH. (2009). Africa today: Culture, economics, religion, security. London and New York: Routledge.
14.
DestlerI. M. (2005). American trade politics. Washington, DC: Institute of International Economics.
15.
De WetP. (2014, January). ‘Motsoaledi: Big pharma’s “satanic” plot is genocide’, Retrieved 29January2014, from http://mg.co.za/article/2014-01-16-motsoaledi-big-pharmas-satanic-plot-is-genocide/
16.
DoyleT.McEachernD. (2008). Environment and politics. London and New York: Routledge.
17.
ElliottL. (2013). Capitalism is about profit, not charity. Mail & Guardian. (Business) (Johannesburg), May, 24–30: 12.
18.
FarmerPGarrettL. (2007). From ‘marvelous momentum’ to health care for all: Success is possible with the right programs. Foreign Affairs, 86(2), 155–159.
19.
FriedmanB. (2012). Obamacare and the court. Foreign Affairs, 91(5), 87–98.
20.
GarrettL. (2005). The lessons of HIV/AIDS. Foreign Affairs, 84(4), 51–64.
21.
GordonB. K. (2003). A high-risk trade policy. Foreign Affairs, 82(4), 105–118.
22.
HertsgaardM. (2002). The eagle’s shadow: Why America fascinates and infuriates the world. New York: Bloomsbury.
23.
HertzN. (2001). The silent take over: Global capitalism and the death of democracy. London: Arrow Books.
24.
HeysC.KillanderM. (Eds). (2010). Compendium of key human rights documents of the African Union. Pretoria: Pretoria University Law Press.
25.
HughesT. (2006). ‘South Africa: The contrarian big African state’, in ClaphmanC.HerbstJ.MillsG. (Eds), Big African states (pp. 155–185). Johannesburg: Wits University Press.
26.
JonesS. G. (2013). The mirage of the Arab spring. Foreign Affairs, 92(1), 55–63.
27.
KárníkováA. (2012). Do they actually matter? The impact of NGOs on the European instrument for democracy and human rights (EIDHR). Perspectives, 20(1), 83–110.
28.
KenyonK. (2012). ‘Reasons for rights: A qualitative approach to Rights use among HIV advocacy groups’, in ViljoenF. (Ed.), Beyond the law: Multi-disciplinary perspectives on human rights (pp. 67–93). Pretoria: Pretoria University Law Press.
29.
Letto-GilliesG. (2012). Transnational corporations and international production: Concepts, theories and effects. Cheltenham, UK and Massachusetts, USA: Edward Elgar Publishing.
30.
LymanP. N.WittelsS. B. (2010). No good deed goes unpunished: The unintended consequences of Washington’s HIV/AIDS Programs. Foreign Affairs, 89(4), 74–84.
MillsG. (2010). Why Africa is poor and what Africans can do about it. London: Penguin.
33.
NevinT. (2013). Foreign hawks circle over magical Rooibos reputation. African BusinessMay, No. 397.
34.
SaulJ. R. (2005). The collapse of globalism: And the reinvention of the world. London: Atlantic Books.
35.
SifileL. (2013), New AIDS drug unveiled. SowetanJohannesburg, May, 15: 2.
36.
SopleV. V. (2012). Managing intellectual property: The strategic imperative. New Delhi: PHI Learning.
37.
SouthallR.MelberH. (Eds). (2001). A new scramble for Africa? Imperialism, investment and development. Scottsville: University of KwaZulu-Natal Press.
38.
StephanH.PowerM.HerveyA. F. (2006). The scramble for Africa in the 21st century: A view from the South. Cape Town: Renaissance Press.
39.
StiglitzJ. (2006). Making globalization work: The next step to global justice. London: Penguin Group.
40.
StubbsR.UnderhillG. R. D. (Eds). (2006). Political economy and the changing global order. Ontario: Oxford University Press.
41.
‘t HoenE. F. M. (2009). The global politics of pharmaceutical monopoly power: Drug patents, access, innovation and the application of the WTO Doha declaration on TRIPS and public health. Diemen: AMB Publishers.
42.
ThompsonC. (2009). ‘The scramble for genetic resources’, in SouthallR.MelberH. (Eds), A new scramble for Africa? Imperialism, investment and development (pp. 299–323). Scottsville, South Africa: University of KwaZulu-Natal Press.
43.
TwinomugishaB. K. (2012). ‘Beyond juridical approaches: What role can the gender perspective play in interrogating the right to health in Africa?’, in ViljoenF. (Ed.), Beyond the law multi-disciplinary perspectives on human right (pp. 41–65). Pretoria: Pretoria University Law Press.
44.
United Nations Development Programme. (2008). Compendium of key documents relating to human rights and HIV in Eastern and Southern Africa. Pretoria: Pretoria University Law Press.
45.
VachaniS.SmithN. C. (2006). ‘Socially responsible pricing: Lessons from the pricing of AIDS drugs in developing countries’, in SubhashC. J.SushilV. (Eds), Multinational corporations and global poverty reduction (pp. 400–434). Cheltenham, UK: Edward Elgar Publishing Limited.
46.
WildS. (2013). ARV plan bounces back. Mail & Guardian, May24–30.
47.
WilksL.NordhaugO. (2013). ‘Ethical, social and environmental responsibilities in MNCs’, in GooderhamP.N.GrøgaardB.NordhaugO. (Eds), International management: Theory and practice (pp. 286–305). Cheltenham: Edward Elgar.
48.
WillettsP. (1997). ‘Transnational actors and international organizations in global politics’, in BaylisJ.SmithS. (Eds), The globalization of world politics: An introduction to international relations (pp. 287–310). Oxford: Oxford University Press.
49.
WoolmanS.SpragueC. (2008). ‘Aspen Pharmacare: Providing affordable generic pharmaceuticals to treat HIV/AIDS and tuberculosis’, in HamannR.WoolmanS.SpragueC. (Eds), The business of sustainable development in Africa: Human rights, partnerships, alternative business models (pp. 285–298). Pretoria: Unisa Press.
50.
ZerkJ. A. (2006). Multinationals and corporate social responsibility: Limitations and opportunities in international law. Cambridge: Cambridge University Press.
